Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 761 |
| PDBID: | 4I0C |
| Chains: | C_B |
| Organism: | Homo sapiens, Camelus dromedarius |
| Method: | XRD |
| Resolution (Å): | 1.95 |
| Reference: | 10.1021/jp403425z |
| Antibody | |
| Antibody: | cAbHuL5 VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Lysozyme C |
| Antigen mutation: | No |
| Durg Target: | P61626 |
Sequence information
Antibody
Chain: C
Mutation: NULL
| >4I0C_C|Chain C, D|cAbHuL5 antibody|Camelus dromedarius (9838) QVQLQESGGGSVQAGGSLRLSCEASGLSTTVMAWFRQAPGKEREGVAAIYTGDGFPYYADSVKGRFTISQDNAKNRMYLQMNSLEPEDTAMYYCAAKTGAFSYGSLWWMSRAYNHWGQGTQVTVSSHHHHHH |
Antigen
Chain: B
Mutation: NULL
| >4I0C_B|Chain A, B|Lysozyme C|Homo sapiens (9606) KVFERCELARTLKRLGMDGYRGISLANWMCLAKWESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGKTPGAVNACHLSCSALLQDNIADAVACAKRVVRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| C: THR30 VAL31 TYR50 GLY52 ASP53 PHE55 PRO56 TYR57 TYR58 ALA100 PHE101 SER102 TYR103 GLY104 SER105 LEU106 B: ARG10 LYS13 ARG14 GLY16 ASP18 GLY19 TYR20 ARG21 GLY22 ILE23 SER24 LEU25 ALA26 ASN27 ILE106 TRP112 VAL121 ARG122 VAL125 GLY129 VAL130 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
